Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05355597 · ClinicalTrials.gov registry record · Phase 2
"The Efficacy of Exparel Versus a Multidrug Cocktail in Soft Tissue Tumors"
A Phase 2 study, sponsored by Atlantic Health System.
- Terminated
- Registry status
- Phase 2
- Development phase
- 116
- Enrollment target
NCT05355597: Clinical Trial Phase 2 study, sponsored by Atlantic Health System.
NCT05355597 is a Phase 2 study that was terminated before completion, run by Atlantic Health System. The registered enrollment target is 116 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (13% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05355597, a Phase 2 study, was terminated before completion, sponsored by Atlantic Health System.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 116 participants
- Enrollment target
Study Summary
The objective of this proposed project is to determine which local anesthetic is more efficacious for use in soft tissue tumors: Exparel (liposomal bupivacaine) or a cocktail of Ropivicaine, Epinepherine, Ketolorac and Clonidine. This study will examine patients' post-operative pain levels as well as their narcotic consumption after removal of a soft tissue tumor while hospitalized and then twice daily through postoperative day 14.
Primary Outcome
Pain will be recorded on a sheet for each patient. Self-reported, patient will describe pain each day on a scale of 1-10 (10 being the worst)
Interventions
- DRUG Exparel Injectable Product
- DRUG Multi-Drug Cocktail (Ropivicaine, Epinephrine, Ketolorac, Clonidine)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 116 participants |
| Start Date | 2021-01-27 |
| Est. Completion | 2025-03-24 |
| Phase | Phase 2 |
Why NCT05355597 stopped before completion
NCT05355597 is an interventional study that assigns participants to a tested intervention. The registered 116 participants enrollment target is mid-sized for trials with a published cap, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (13% lower).
The record links to 0 conditions, and to 2 interventions - of which Exparel Injectable Product is the first listed.
NCT05355597 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05355597 about?
NCT05355597 is a clinical study titled ""The Efficacy of Exparel Versus a Multidrug Cocktail in Soft Tissue Tumors"". The objective of this proposed project is to determine which local anesthetic is more efficacious for use in soft tissue tumors: Exparel (liposomal bupivacaine) or a cocktail of Ropivicaine, Epinepherine, Ketolorac and Clonidine. This study will examine patients' post-operative pain levels as well a...
What is the current status of trial NCT05355597?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 116 participants. The study started on 2021-01-27. Estimated completion is 2025-03-24.
What interventions are being tested in trial NCT05355597?
The interventions under investigation include: Exparel Injectable Product (DRUG), Multi-Drug Cocktail (Ropivicaine, Epinephrine, Ketolorac, Clonidine) (DRUG).
Who is sponsoring clinical trial NCT05355597?
This trial is sponsored by Atlantic Health System, which has 43 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05355597's enrollment target sits among peer trials
116 623rd of 2000 higher than 1,375 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03014687 · 116 participants · Phase 4
Prophylactic Oral Antibiotics on Sinonasal Outcomes Following Endoscopic Transsphenoidal Surgery for Pituitary Lesions
- NCT03214562 · 116 participants · Phase 1
Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory Acute Myeloid Leukemia
- NCT03847467 · 116 participants · Phase 1
Pilot and Feasibility Study of 2'-FL as a Dietary Supplement in IBD Patients Receiving Stable Maintenance Anti-TNF Therapy
- NCT04222413 · 116 participants · Phase 1
Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI